Prevention of Type 2 Diabetes and Body Weight Maintenance

An analysis from the SELECT trial showed a 73% reduction in the progression to type 2 diabetes in individuals without diabetes. Weight loss was a significant factor, but other effects not directly related to weight loss were observed, possibly due to the GLP-1 agonist's ability to prevent beta cell loss. A study on the newer agent PEMVITITIDE, a GLP-1 and glucagon dual receptor agonist, demonstrated not only weight loss effects but also preservation of lean mass, addressing an issue seen in other GLP-1 agonists.